A method of diagnosing and treating urinary tract obstruction that includes obtaining a urine sample from a human patient; detecting whether a predetermined uroepithelial peptide or predetermined urinary protein is present in the urine sample by either contacting the urine sample with an anti-uroepithelial peptide antibody and detecting binding between the uroepithelial peptide and the antibody or contacting the urine sample with an anti-urinary protein antibody and detecting binding between the urinary protein and the antibody; diagnosing the patient with urinary tract obstruction when the presence of either the predetermined uroepithelial peptide or predetermined urinary protein is detected; and operatively or non-operatively treating the patient to correct or remove the urinary tract obstruction.

The present invention relates to a method of classifying a sample of a patient that suffers from or being at risk of developing urothelial or bladder cancer, said method comprising the steps of: a) determining in said sample from said patient, the presence or absence of alteration in an FGFR gene and/or the expression level of at least one gene encoding for a receptor selected from the group consisting of FGFR1, FGFR2, FGFR3 or FGFR4, and b) classifying the sample of said patient from the outcome of step a) into one of at least two classifications, said classifications comprising good and poor prognosis for treatment with an anti-cancer agent.

The present invention relates to a method for preserving urinary cells, the method comprising the step of contacting a urine sample obtained from a patient with a buffer substance suitable to create and/or maintain a pH value in the range of 6 to 8, particularly approx. 7, within said urine sample, and a formaldehyde releasing compound.

The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.

The present invention relates in general to the field of muscle disease. In particular, the invention relates to a method for determining if a subject has sarcopenia or has an increased risk of developing sarcopenia. A method of predicting the responsiveness of said subject to nutritional intervention is also provided.

The invention provides a method for preparing an expanded renal (kidney) tissue sample suitable for microscopic analysis. Expanding the kidney sample can be achieved by binding, e.g., anchoring, key biomolecules to a polymer network and swelling, or expanding, the polymer network, thereby moving the biomolecules apart as further described herein. As the biomolecules are anchored to the polymer network, isotropic expansion of the polymer network retains the spatial orientation of the biomolecules resulting in an expanded, or enlarged, kidney sample.

A method for treating chronic inflammatory conditions in the lower urinary tract, the method comprising administering to a patient in need thereof, an effective amount of a reagent selected from the group consisting of IL-1β inhibitors and MMP inhibitors, or proteins selected from ASC or NLRP-3 is provided. Diagnostic methods are also described and claimed. The present disclosure further relates to an IL-1 inhibitor for use in a method of treating, alleviating or reducing pain and pain related symptoms of chronic pelvic pain syndrome. The IL-1 inhibitor may be an IL-1 receptor antagonist. The IL-1 inhibitor may be anakinra. The chronic pelvic pain syndrome may be a urological pain syndrome, a gynecological pain syndrome of the external genitalia, an internal pelvic pain syndrome and a gastrointestinal pelvic pain syndrome.

The invention provides a method of diagnosing overactive bladder disorder (OAB), the method comprising: measuring the concentrations of one or more of adenosine triphosphate (ATP), acetylcholine (ACh), nitric oxide (NO) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001; ACh/Cr to 0.1; NO to 20000; IL-5/Cr to 100; wherein the likelihood of having OAB (p.sub.OAB)=1/1+e.sup.−x, where X=one or more of the following: (a) (−2.688±1.050)+5.472±2.098×subject's age+1.356±0.559×Gender (Female=1, Male=0)+(−7.998±40.273)×[IL-5/Cr]; (b) (−2.141±0.966)+4.506±1.902×subject's age+1.034±0.519×Gender (Female=1, Male=0)+(−5294.063±9075.456)×[ACh/Cr]; (c) (−2.825±1.072)+5.964±2.167×subject's age+1.312±0.562×Gender (Female=1, Male=0)+17.790±58.762×[IL-5/Cr]+(−9180.821±12700.057)×[ACh/Cr]; (d) (−2.993±1.197)+5.580±2.309×subject's age+1.724±0.719×Gender (Female=1, Male=0)+63.571±73.444×[IL-5/Cr]+(−0908.523±13606.752)×[ACh/Cr]+(−566.991±636.589)×[ATP/Cr]; (e) (−3.090±1.200)+5.393±2.256×subject's age+1.797±0.717×Gender (Female=1, Male=0)+34.767±56.331×[IL-5/Cr]+(−562.743±629.316)×[ATP/Cr]; or (f) (−2.650±1.067)+5.516±2.120×subject's age+1.389±0.583×Gender (Female=1, Male=0)+(−4.060±45.238)×[IL-5/Cr]+(−1.456±6.833)×[NO/Cr]; and wherein a pOAB above a threshold indicates that the subject has a high likelihood of having or developing OAB and a pOAB below a threshold indicates that the subject does not have OAB.

An in vitro method for diagnosing a urological cancer comprising the comparison of a secretome of isolated cells from a urine sample from a patient to be diagnosed with respect: either to a reference secretome obtained from secretions of healthy isolated cells from a urine sample from a healthy person, or to a reference secretome obtained from secretions of healthy cells which are derivatives of standard cell line cultures, characteristic of a determined urological organ, the secretome and the reference secretome being constituted of all the components forming the respective secretions thereof.

The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.